Equities Analysts Set Expectations for AVXL Q2 Earnings

Anavex Life Sciences Corp. (NASDAQ:AVXL) – Investment analysts at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for Anavex Life Sciences in a research note issued on Tuesday, February 10th. HC Wainwright analyst R. Selvaraju now anticipates that the biotechnology company will post earnings of ($0.07) per share for the quarter, up from their prior forecast of ($0.11). HC Wainwright currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Anavex Life Sciences’ current full-year earnings is ($0.69) per share. HC Wainwright also issued estimates for Anavex Life Sciences’ Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.11) EPS and FY2026 earnings at ($0.33) EPS.

Several other brokerages have also weighed in on AVXL. D. Boral Capital restated a “buy” rating and issued a $24.00 price objective on shares of Anavex Life Sciences in a report on Monday, February 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Anavex Life Sciences in a research report on Monday, December 29th. Finally, Jones Trading lowered Anavex Life Sciences from a “buy” rating to a “hold” rating in a research report on Friday, October 24th. Two research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $22.00.

Anavex Life Sciences Trading Up 0.3%

Shares of NASDAQ AVXL opened at $3.93 on Thursday. Anavex Life Sciences has a 1 year low of $2.86 and a 1 year high of $13.99. The firm’s 50-day moving average is $4.26 and its 200-day moving average is $6.87. The firm has a market capitalization of $364.19 million, a PE ratio of -8.54 and a beta of 1.21.

Anavex Life Sciences (NASDAQ:AVXL) last posted its quarterly earnings results on Monday, February 9th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.04.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Delta Asset Management LLC TN increased its holdings in shares of Anavex Life Sciences by 9.1% in the second quarter. Delta Asset Management LLC TN now owns 12,000 shares of the biotechnology company’s stock worth $111,000 after acquiring an additional 1,000 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in Anavex Life Sciences by 1.5% in the second quarter. Ameriprise Financial Inc. now owns 85,990 shares of the biotechnology company’s stock valued at $793,000 after buying an additional 1,233 shares in the last quarter. Ameritas Investment Partners Inc. boosted its holdings in shares of Anavex Life Sciences by 22.3% in the second quarter. Ameritas Investment Partners Inc. now owns 8,535 shares of the biotechnology company’s stock valued at $79,000 after buying an additional 1,559 shares during the period. BNC Wealth Management LLC increased its position in shares of Anavex Life Sciences by 19.5% during the fourth quarter. BNC Wealth Management LLC now owns 12,250 shares of the biotechnology company’s stock worth $44,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Independent Advisor Alliance raised its holdings in shares of Anavex Life Sciences by 5.7% during the third quarter. Independent Advisor Alliance now owns 47,799 shares of the biotechnology company’s stock worth $425,000 after acquiring an additional 2,593 shares during the period. 31.55% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Anavex Life Sciences

Here are the key news stories impacting Anavex Life Sciences this week:

• Positive Sentiment: HC Wainwright reiterated its “Buy” rating and raised near‑term and FY2026 EPS forecasts, signaling improved analyst confidence and a $20 target that could support upside. HC Wainwright Reiterates “Buy” Rating for Anavex Life Sciences (NASDAQ:AVXL)
• Positive Sentiment: HC Wainwright raised Q2–Q4 and FY2026 EPS estimates (e.g., Q4 from -$0.14 to -$0.11; FY from -$0.46 to -$0.33), suggesting expected operational or clinical progress that could improve future profitability. What is HC Wainwright’s Estimate for AVXL Q1 Earnings?
• Positive Sentiment: Zacks upgraded AVXL to a Rank #2 (Buy), reflecting growing optimism about the company’s earnings outlook and potentially attracting buy‑side interest. Anavex Life Sciences (AVXL) Upgraded to Buy
• Positive Sentiment: Anavex’s latest quarterly report beat EPS expectations (reported -$0.06 vs. consensus -$0.10), a near‑term fundamental positive that can support price momentum. MarketBeat AVXL profile
• Neutral Sentiment: Reports show a spike in short‑interest figures that are recorded as 0 shares and NaN changes — data appears erroneous or incomplete, so it’s unclear whether short covering or new shorts are influencing trading. (No reliable source link available.)
• Negative Sentiment: Despite upgrades, consensus still forecasts negative FY2026 EPS (-$0.69 before HC Wainwright adjustments), and the stock sits below both the 50‑day (~$4.27) and 200‑day (~$6.92) moving averages, indicating technical resistance and lingering macro/sector risk. MarketBeat AVXL profile

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.